Is Sermorelin Legal in North Carolina?

The Short Answer on Sermorelin's Legal Status in North Carolina

Sermorelin is not a controlled substance. No federal statute and no North Carolina General Statute lists it under a prohibited or scheduled category. A licensed prescriber in North Carolina can legally order it, and a 503A or 503B compounding pharmacy can legally prepare it, provided the prescription meets standard requirements.

"legal" and "straightforward" are not the same thing. The regulatory path runs through overlapping federal and state frameworks, and getting those details wrong creates real risk for both patients and providers.

Why Sermorelin Has No FDA-Approved Brand Product

Sermorelin acetate was originally sold under the brand name Geref (Serono). The manufacturer voluntarily withdrew Geref from the U.S. Market in 2008. That withdrawal was commercial, not safety-driven. The FDA did not pull the approval for a safety reason, which matters: the drug is not on the FDA's list of withdrawn or recalled drugs that compounders are prohibited from preparing.

Because no branded product exists today, access depends entirely on compounding pharmacies regulated under the Federal Food, Drug, and Cosmetic Act (FDCA), specifically Sections 503A and 503B. FDA compounding guidance is available here.

The 503A vs. 503B Distinction

503A pharmacies are traditional compounding pharmacies. They prepare drugs for an identified individual patient based on a valid prescription from a licensed practitioner. They are regulated primarily by state pharmacy boards, with federal oversight under the FDCA.

503B outsourcing facilities are federally registered, operate under current Good Manufacturing Practice (cGMP) standards, and can produce larger batches without patient-specific prescriptions, typically supplying clinics and medical practices. The FDA maintains a current list of registered 503B outsourcing facilities.

For an individual patient in North Carolina, the most common path is a 503A pharmacy filling a patient-specific prescription. For clinics administering sermorelin in-office, a 503B facility is the appropriate source.

Federal Law: Where Sermorelin Actually Stands

Not on the DEA Controlled Substances List

The Drug Enforcement Administration's schedule of controlled substances (Schedule I through V) does not include sermorelin. The DEA's current scheduling list can be confirmed at the DEA Diversion Control Division. Growth hormone-releasing hormone (GHRH) analogs are not categorized as anabolic steroids or growth hormone itself under the Anabolic Steroids Control Act. Sermorelin stimulates the pituitary to release endogenous growth hormone rather than introducing exogenous growth hormone directly. That distinction keeps it outside the stricter regulatory framework that governs somatropin (rHGH).

The FDA Bulk Drug Substances Issue

This is where the picture gets more complex. The FDA has authority under Section 503A and 503B to publish lists of bulk drug substances that may or may not be used in compounding. Sermorelin has been nominated for inclusion on the 503A bulk drug substances list. As of this writing, FDA has not finalized a ruling placing sermorelin on the "Category 1" list (substances that may be used) or "Category 2" list (substances that raise safety concerns).

That interim status means compounding pharmacies are operating in a zone that requires careful monitoring. Most reputable 503A pharmacies are currently compounding sermorelin while its nomination is under review. Patients and providers should confirm with their specific pharmacy that it is monitoring FDA rulemaking and will notify them of any change. The FDA's current bulk drug substances lists for 503A compounding are published here.

Anti-Doping and Athletic Contexts

The World Anti-Doping Agency (WADA) and the U.S. Anti-Doping Agency (USADA) prohibit sermorelin in competitive athletes. This is not a legal prohibition under U.S. Law but a condition of participation in sanctioned sports. Patients who compete in tested sports should disclose sermorelin use to their sports medicine physician before starting treatment. WADA's prohibited list is maintained at wada-ama.org.

North Carolina State Law: What Applies to Sermorelin

The North Carolina Medical Practice Act

The North Carolina Medical Practice Act (N.C.G.S. Chapter 90, Article 1) governs physician prescribing authority. A licensed MD or DO may prescribe any non-scheduled drug with a legitimate medical purpose and within the standard of care. Sermorelin fits this framework when prescribed for documented growth hormone deficiency, short stature with a GH axis finding, or other evidence-based indications.

Nurse practitioners and physician assistants practicing under a supervising or collaborating physician agreement may also prescribe sermorelin in North Carolina, consistent with their scope of practice under N.C.G.S. § 90-18.2 and § 90-18.1.

The North Carolina Board of Pharmacy

The North Carolina Board of Pharmacy regulates in-state compounding pharmacies under N.C.G.S. Chapter 90, Article 4A, and enforces compliance with both state compounding rules and FDCA requirements. A compounding pharmacy licensed in North Carolina and preparing sermorelin must:

1. Hold a valid North Carolina pharmacy permit.
2. Compound only pursuant to a valid patient-specific prescription (503A) or operate as a federally registered outsourcing facility (503B).
3. Meet USP <797> sterile compounding standards for injectables.

Patients ordering sermorelin from out-of-state compounding pharmacies via mail should verify that the pharmacy holds an out-of-state pharmacy permit issued by the North Carolina Board of Pharmacy. The Board's permit verification tool is available at ncbop.org.

Telehealth Prescribing in North Carolina

North Carolina's telehealth laws allow prescribers to establish a valid patient-provider relationship via synchronous audio-video consultation, which satisfies the prescribing standard for non-controlled substances including sermorelin. Senate Bill 105 (2021 session) expanded telehealth parity in North Carolina. A provider seeing a North Carolina patient via telehealth must hold a North Carolina license or qualify under the State's reciprocity provisions.

This matters for patients considering national telehealth hormone clinics: the prescribing physician must be licensed in North Carolina. Any clinic that does not verify state licensure before prescribing is operating outside the law.

Clinical Indications: When Is Sermorelin Prescribed?

Sermorelin is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH). It acts on the pituitary gland to stimulate pulsatile release of endogenous growth hormone rather than replacing it exogenously. Basic pharmacology is summarized in the NCBI reference here.

Documented Indications

The primary evidence-based indication is growth hormone deficiency (GHD) in adults and children. A 1994 multicenter study by Thorner et al. Published in the Journal of Clinical Endocrinology and Metabolism found that sermorelin significantly increased IGF-1 levels in GHD children over 12 months compared to placebo (P<0.001). Thorner MO et al., JCEM 1994, available on PubMed.

A separate randomized trial by Walker et al. (1996, N=112) demonstrated that nightly sermorelin acetate 30 mcg/kg/day produced mean IGF-1 normalization in 78% of GHD children at 6 months. Walker JL et al., JCEM 1996.

Adult prescribing for age-related GH decline (sometimes called somatopause) is a more debated area. The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults states: "We recommend against making a diagnosis of GHD solely on the basis of low IGF-1 levels without confirmatory stimulation testing." Clinicians following this guideline should document stimulation test results before initiating sermorelin. Endocrine Society GHD Guideline 2019.

Off-Label Use Patterns

Many clinics prescribe sermorelin as part of anti-aging or body composition protocols. These uses are off-label. Prescribers must document their clinical reasoning and obtain informed consent that includes disclosure of the off-label nature of the prescription. North Carolina's standard of care does not prohibit off-label prescribing, but it does require documentation that supports medical decision-making.

How to Get Sermorelin Legally in North Carolina

The following step-by-step access framework is the HealthRX editorial team's synthesis of the applicable federal and North Carolina regulatory requirements. It is designed to help patients and clinicians verify that each stage of the prescribing and dispensing chain is lawful.

Step 1: Obtain a Complete Medical Evaluation

A valid sermorelin prescription starts with a documented clinical evaluation. This must include:

• A thorough history of symptoms consistent with GHD or GHRH-related deficiency (fatigue, decreased lean muscle mass, increased adiposity, impaired sleep architecture).
• Baseline laboratory work: IGF-1 (age- and sex-adjusted), fasting insulin, fasting glucose, HbA1c, comprehensive metabolic panel, and thyroid panel.
• For suspected adult GHD, an arginine-GHRH stimulation test or insulin tolerance test per Endocrine Society criteria.

No legitimate prescriber should issue a sermorelin prescription from a symptom questionnaire alone.

Step 2: Receive the Prescription from a Licensed Provider

The prescribing clinician must hold an active North Carolina medical or advanced-practice license, or a valid North Carolina telehealth license. The prescription must specify:

• Drug name (sermorelin acetate)
• Concentration (typically 2 mg/mL to 6 mg/mL in bacteriostatic water)
• Dose (commonly 0.2 mg to 0.3 mg subcutaneous injection at bedtime)
• Quantity and refills
• Indication documented in the medical record

Step 3: Verify Your Compounding Pharmacy's Credentials

Before filling, confirm:

1. The pharmacy holds a valid permit from the North Carolina Board of Pharmacy (or a valid out-of-state permit if shipping into NC).
2. The pharmacy compounds under USP <797> sterile standards.
3. The pharmacy is monitoring FDA's 503A bulk drug substances rulemaking and has a policy for notifying patients if sermorelin's status changes.

Avoid any pharmacy that offers sermorelin without requiring a prescription or that ships product labeled "for research use only."

Step 4: Follow Up at 3 and 6 Months

Monitoring should include repeat IGF-1 (targeting the mid-normal range for age and sex), fasting glucose (sermorelin may transiently affect insulin sensitivity), and a symptom review. The Endocrine Society guideline recommends titrating GH-axis therapies to keep IGF-1 below the upper limit of normal to reduce the theoretical risk of adverse effects. Endocrine Society GHD Guideline 2019.

Red Flags: What Illegal Access Looks Like

Not every source offering sermorelin in North Carolina is operating legally. Watch for:

• No prescription required. Any website selling sermorelin as a "research chemical" or without a prescription is not operating legally under the FDCA. Purchasing from these sources exposes the buyer to product-quality risks and potential legal liability.
• Prescriptions issued without a synchronous consultation. A questionnaire-only or asynchronous-only encounter does not establish a valid prescriber-patient relationship under North Carolina law for this type of drug.
• Pharmacies without verifiable NABP accreditation or state permits. The National Association of Boards of Pharmacy's ".pharmacy" verification program or a direct lookup with the NC Board of Pharmacy are the two reliable verification methods.
• Dosing claims far outside clinical ranges. Doses above 0.5 mg nightly are outside standard published protocols and may indicate a non-clinical operation.
• Products mixed with BPC-157, TB-500, or other peptides without individual prescriptions. Each compounded active ingredient requires its own prescribing rationale and must appear in the prescription.

Safety Profile and Contraindications

Sermorelin's adverse-effect profile is generally mild. The most commonly reported reactions in clinical trials were injection-site redness (approximately 17% of patients in the Thorner 1994 trial), transient flushing, and headache. Serious adverse events were rare. Thorner MO et al., JCEM 1994.

Contraindications Worth Knowing

Sermorelin should not be initiated in patients with:

• Active malignancy (GH-axis stimulation is contraindicated in active cancer per Endocrine Society guidance).
• Untreated hypothyroidism (thyroid hormone is required for normal GH axis function; sermorelin's effect will be blunted and interpretation of IGF-1 response unreliable).
• Diabetic retinopathy or uncontrolled diabetes (GH stimulation may worsen retinal disease and insulin resistance).
• Pregnancy or lactation (no safety data available).

Drug Interactions

No formal pharmacokinetic interaction studies for sermorelin exist in the current literature. Clinically, glucocorticoids at pharmacological doses suppress the GH axis and may reduce sermorelin's effectiveness. Insulin and antidiabetic agents may need dose adjustment if IGF-1 and GH rise substantially.

Comparing Sermorelin to Other Growth Hormone Secretagogues

Sermorelin is one of several peptides that stimulate GH secretion. Patients frequently ask how it compares to ipamorelin, CJC-1295, or tesamorelin.

• Tesamorelin (Egrifta) holds FDA approval specifically for HIV-associated lipodystrophy. It is a GHRH analog with a longer half-life than sermorelin. Using it off-label outside that indication is more legally complex because FDA-approved drugs carry stronger off-label prescribing scrutiny.
• Ipamorelin and CJC-1295 are growth hormone secretagogues that work via the ghrelin receptor rather than the GHRH receptor. They are also on the 503A bulk substances nomination list, with FDA review ongoing. Their legal path in North Carolina is the same as sermorelin's, subject to the same pharmacy verification requirements.
• Somatropin (rHGH) is FDA-approved and federally regulated as a Schedule III-adjacent drug under the Anabolic Steroid Control Act. Its legal prescribing requirements are substantially stricter than sermorelin's.

FDA information on tesamorelin (Egrifta).

Cost and Insurance Considerations in North Carolina

Compounded sermorelin is not covered by commercial insurance or Medicare/Medicaid because there is no FDA-approved product from which a coverage determination can be made. Patients pay out-of-pocket.

Current market pricing in North Carolina runs approximately $150 to $350 per month depending on the compounding pharmacy, concentration, and whether the prescription is bundled with clinical monitoring. Telehealth consultation fees (typically $100 to $250 for an initial visit) are separate. Some health savings account (HSA) and flexible spending account (FSA) plans do cover compounded prescription medications; patients should confirm eligibility with their plan administrator.